A Systems Analysis of Mitotic Apparatus Inhibitors Defines a Response Network for Breast Cancer.
Zhanying Hu(Baruch S. Blumberg Institute), Joe W. Gray(University of Newcastle Australia), Richard Wooster(GlaxoSmithKline (United States)), Jian‐Hua Mao(Cancer Research Institute), James E. Korkola(Oregon Health & Science University), Bernhard H. F. Weber(University of Regensburg), Shenda Gu, Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Marc E. Lenburg(Boston University), W.-L. Kuo(Lawrence Berkeley National Laboratory), N. Wang(Lawrence Berkeley National Laboratory), Nora Bayani(Lawrence Berkeley National Laboratory), Guanhao Huang(École Polytechnique Fédérale de Lausanne)
Cited by 1
Related Papers
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
|Cell|2020|602
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
|Journal of Clinical Investigation|2012|591
Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target
|Cancer Cell|2013|571
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505